| Literature DB >> 35204790 |
Lucas de Freitas Pedrosa1, Avraham Raz2, João Paulo Fabi1,3,4.
Abstract
Galectin-3 is the only chimeric representative of the galectin family. Although galectin-3 has ubiquitous regulatory and physiological effects, there is a great number of pathological environments where galectin-3 cooperatively participates. Pectin is composed of different chemical structures, such as homogalacturonans, rhamnogalacturonans, and side chains. The study of pectin's major structural aspects is fundamental to predicting the impact of pectin on human health, especially regarding distinct molecular modulation. One of the explored pectin's biological activities is the possible galectin-3 protein regulation. The present review focuses on revealing the structure/function relationship of pectins, their fragments, and their biological effects. The discussion highlighted by this review shows different effects described within in vitro and in vivo experimental models, with interesting and sometimes contradictory results, especially regarding galectin-3 interaction. The review demonstrates that pectins are promissory food-derived molecules for different bioactive functions. However, galectin-3 inhibition by pectin had been stated in literature before, although it is not a fully understood, experimentally convincing, and commonly agreed issue. It is demonstrated that more studies focusing on structural analysis and its relation to the observed beneficial effects, as well as substantial propositions of cause and effect alongside robust data, are needed for different pectin molecules' interactions with galectin-3.Entities:
Keywords: bioactive polysaccharides; galectin-3; galectin-3 inhibition; pectin; structure and function
Mesh:
Substances:
Year: 2022 PMID: 35204790 PMCID: PMC8961642 DOI: 10.3390/biom12020289
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Schematic representation of major pectin components in chair conformation. HG—homogalacturonan, composed of linear α-1,4-d-galactopyranuronic acids; RG-I—intercalated α-d-galactopyranuronic acids and α-l-rhamnopyranose through α-1,4 and 1,2 glycosidic bindings; AG-I—β-1,4-d-galactopyranose with occasional O-3 α-l-arabinofuranose; AG-II—β-1,3-d-galactopyranose with O-6 α-l-arabinofuranose/arabinogalactans. Arabinans and galactans consist of linear α-1,5-l-arabinofuranoses and β-1,4-d-galactopyranoses, respectively.
Figure 2Schematic representation of major pectin components in Symbol Nomenclature for Glycans (SNFG-B) [9] model. Different glycosidic bounds common to pectins are illustrated.
Figure 3Schematic representation of (patho)physiological effects of galectin-3. As it is demonstrated, the physiology is separated by a thin line from the pathological scenario, such as the extracellular matrix (ECM) secretion stimuli or the chemotactic signaling for infiltrative immune cells. Bcl-2—B-cell lymphoma 2; ERK—extracellular signal-regulated kinases; NT—N-terminal tail/domain; PKC—protein kinase-C; ROS—reactive oxygen species.
Figure 4Galectin-3 crystalized tertiary structure X-ray diffraction, PDB ID 49RB [75,80,81]. (A) Gal-3 complete CRD, with the anti-parallel β-sheet sandwich; (B) CRD S-face β-sheets (S1–S6), which holds the ABCDE subsites. The NWGR motif is highlighted because of their biochemical importance; (C) CRD F-face β-sheets (F1–F5, also numbered as B-9, -8, -7, -2, and -11, respectively); (D) Schematic representation of β-d-galactopyranosyl-1,4- β-D glucopyranose (β-Lactose) binding at the canonical S-face. The hydrogens atoms are colored as red, the hydrogen bonds as blue dotted lines, and the lactose chain as orange. The binding is stronger at the C subsite (between S4 and S5) amino acids and the β-d-galactopyranosyl residue.
Figure 5Hypothetical interaction of RG-I fragments with both F and S-face of Galectin-3 simultaneously. Here, the main protagonists would be the β-d-galactopyranose and α-d-galactopyranuronic acid residues and would not act like specific pharmacological inhibitors, but maybe as potential Gal-3-ligand blockers through multivalency or allosteric occupation. Hydrogen bonds are represented by the blue dotted lines. PDB ID 49RB [75,80,81].
Polysaccharide-Gal-3 binding articles summary.
| Authors | Polysaccharide Residue | Analysis Method | Binding Evaluation |
|---|---|---|---|
| Wu et al., 2020 [ | RG-I from citrus canning process water | Surface plasmon resonance | Smooth binding curve through SPR with decreased affinity with galactan side-chain removal |
| Zhang et al., 2016 [ | MCP, RG-I-4, and p-galactan | Gal-3 hemagglutination, bio-layer interferometry, and surface plasmon resonance | RG-I-4 demonstrated higher Gal-3 avidity in comparison to the other two polysaccharides, with a KD at sub-micromolar range (RG-I-4 and p-galactan), but no significant result when testing competitive assays with known S-face inhibitors such as lactose |
| Gao et al., 2013 [ | Ginseng RG-I-4 domain | Gal-3 hemagglutination and surface plasmon resonance | RG-I-4 inhibited G3H and was bound specifically to CRD with high affinity with Ara residue location in the RG-I, changing the activity detected at the G3H assay |
| Gunning, Bongaerts, Morris et al., 2009 [ | RG-I, PG, and galactans | Atomic force microscopy, fluorescence microscopy, nuclear magnetic resonance, and flow cytometry | Galactan binding to Gal-3 is lectin-saccharide highly specific, while RG-I has low specificity, and PG was not specific. The data suggest that the lesser “sterical crowding” of the galactans alongside its beta-1,4 linear chain could be the reason for the better performance observed |
| Shi et al., 2017 [ | Ginseng RG-I-3A domain | Bio-layer interferometry, Gal-3 hemagglutination | Binding kinetics of RG-I-3A showed a high binding affinity with a KD of 28 nM through and also presented notable G3H inhibition |
| Zhang et al., 2017 [ | MCP-derived RG-I and HG portions | Gal-3 hemagglutination, bio-layer interferometry, ELISA, and nuclear magnetic resonance | Gal-3 bound to both portions separately but with a much more notable avidity when a combination of them (RG + HG) is performed, suggesting that this interaction exposes more binding sites at the lectin |
| Miller et al., 2015 [ | Galactomannans (GM) and polymannan | Nuclear magnetic resonance | The primary binding surface of the GM’s located mainly at F-face beta-sheets (7,8 and 9) |
| Zheng et al., 2020 [ | MCP-derived HGs of varying molecular weights | Nuclear magnetic resonance heteronuclear single quantum coherence spectroscopy and crystallography | Higher molecular weight HGs demonstrated more perturbances at F-face resonances and involved more S-face beta-sheets at the binding footprint. A possible binding of Gal-3 to the non-terminal HG sites is suggested, and it is shown a different S-face binding pattern of HG’s compared to lactose |
| Miller et al., 2019 [ | Galactan oligosaccharides of varying chain lengths | Nuclear magnetic resonance heteronuclear single quantum coherence spectroscopy | Binding affinity at the terminal non-reducing end of the galactans in the CRD S-face (beta-sheets 4, 5, and 6 chemical shifts mostly) increases with the increase in chain length |
| Zhao et al., 2017 [ | Pumpkin RG-I-containing pectin | Surface plasmon resonance | Moderate binding affinity towards Gal-3 through SPR, with a fast association between protein and polysaccharide (KA) and slow dissociation (KD) |
| Miller et al., 2017 [ | Ginseng RG-I-4 domain | Nuclear magnetic resonance heteronuclear single quantum coherence spectroscopy | Epitopes from RG-I-4 bind to three different labeled Gal-3 sites, two at the CRD and another one at NT. At lower concentrations, the F-face site is more activated, turning to S-face at higher ones |
Summary of observed experimental effects in manuscripts studying pectin and its fragments.
| Authors | Treatment | Study Type | Treatment Target | Observed Experimental Effects |
|---|---|---|---|---|
| Pedrosa, Lopes and Fabi, 2020 [ | Papaya pectin acid and neutral fractions | In vitro | HCT 116, HT-29, and HCT-116 Gal-3−/− | Gal-3-mediated agglutination inhibition, cell viability decrease in both WT and knockout cells (suggesting Gal-3 independent pathways) |
| Chen et al., 2018 [ | SCFAs | In vivo | Male apoE−/− mice | Stimulation of Lxrα mediated genes expression related to intestinal cholesterol uptake and excretion; improved blood lipid profiles and anti-atherosclerotic property |
| Li, Zhang, and Yang 2018 [ | CP | In vivo | Healthy male C57BL/6J mice | Pectin-supplemented high-fat diet mice had reduced lower liver damage, lipid accumulation, and total serum triglyceride |
| Brouns et al., 2012 [ | Different DM and MW apple and citrus pectin (CP) | Human intervention | Mildly hyper-cholesterolemic men and women | Higher DM apple and citrus pectin lowered between 7 and 10% low-density lipoprotein cholesterol (LDL-C) compared to control |
| Liu et al., 2016 [ | CP | In vivo | Male Sprague-Dawley rats with induced type 2 diabetes | Enhanced glucose tolerance, blood lipid levels, reduced insulin resistance, pAKT expression upregulation, and glycogen synthase kinase 3 β (GSK3β) downregulation |
| Fotschki et al., 2014 [ | Apple fiber (low pectin) | In vivo | Male Wistar rats | Disaccharidase activity reduction, higher SCFA production, reduced serum glucose concentration |
| Prado et al., 2019 [ | Chelate-soluble fraction of papaya pectin | In vitro | HCT 116 and HT-29 human colon cancer cells | Gal-3-mediated agglutination inhibition, similar to lactose control; pre-treatment with lactose suggests cell Gal-3 independent proliferation reduction for one of the fractions (3CSF) |
| Wu et al., 2020 [ | CP fragments | In vitro | MCF-7 human breast cancer and A549 human lung carcinoma | Significant binding affinities to Gal-3; dose-responsive cell proliferation inhibition in vitro, not necessarily related to Gal-3 |
| Gao et al., 2013 [ | MCP, ginseng pectin fractions, potato galactans, and RG-I | In vitro | HT-29 human colon cancer cell line | RG I-4 from ginseng strongly inhibited Gal-3 mediated hemagglutination; better inhibition of cell adhesion and homotypic cell aggregation than lactose |
| Stegmayr et al., 2016 [ | MCP | In vitro | JIMT-1 breast cancer cells | No Gal-3 inhibition was detected; however, MCP pre-incubation resulted in the accumulation of Gal-3 molecules around intracellular vesicles |
| Prado et al., 2020 [ | Papaya pectins from different ripening periods | In vitro | THP-1 human monocytic cell | Different TLR’s activation and inhibition depend on the ripening period |
| Hu et al., 2020 [ | Lemon pectin | In vitro | Human pancreatic beta-cell | Unspecific and unspecified reduction of deleterious effects of inflammatory cytokines with very low (5%) degree of esterification pectin at cell culture |
| Xu et al., 2020 [ | MCP | In vivo | Male Wistar rats | Down-regulation of Gal-3, TLR, and MyD88, decreased expression of IL-1β, IL-18, and TNF-α |
| Maxwell et al., 2016 [ | Sugar beet and CP | In vitro | HT-29 human colon cancer cell line | Cell proliferation control and induction of apoptosis |
| Pynam and Dharmesh, 2019 [ | Bael fruit pectin fragments | In vitro and in vivo | Healthy Swiss albino mice and B16F10 cell line | Microbiota protection, tyrosinase down-regulation, Gal-3 binding, downregulation of Gal-3 gene, IL10 and IL17 cytokines |
| Fang et al., 2018 [ | MCP | In vitro | Human urinary bladder cancer (UBC) cells | Gal-3 down-regulation and inactivation of Akt signaling pathway, a decrease in Cyclin B1, G2/M phase arrest, Caspase-3 activation |
| Hossein et al., 2019 [ | MCP | In vitro | SKOV-3 and SOC (serous ovarian cancer) cells | Synergistic effect of PTX and MCP increasing caspase-3 activity and decreasing cyclin D1 expression level |
| Abu-Elsaad and Elkashef, 2016 [ | MCP | In vivo | Adult male Sprague-Dawley rats | Decreased liver fibrosis and necroinflammation, a decrease in MDA, TIMP-1, Col1A1, and Gal-3, increase in Caspase-3, gluthatione, and superoxide dismutase expression |
| Martinez-Martinez et al., 2016 [ | MCP | In vivo | Adult male Wistar rats | Attenuation of renal fibrosis-related biomarkers, osteopontin, cytokine A2, albuminuria and TGF-β1 |
| Calvier et al., 2015 [ | MCP | In vivo | Adult male Wistar rats, C57BJ6 WT and Gal-3−/− mice | Reverted fibrosing markers and Gal-3 augmentation levels, similarly to spironolactone |
| Li et al., 2018 [ | MCP | In vitro and in vivo | HEK293 cells and C57BL/6 male mice | Amelioration of renal interstitial fibrosis, lower collagen I and fibronectin in the kidney, reduced IL-1β mRNA levels, lower Gal-3 expression |
| Prud’homme et al., 2019 [ | MCP | Cohort and in vivo | C57BL6/J and C57BL6/J Gal-3 KO male mice | Cardiac fibrosis induced by model prevented by MCP treatment, IL-1β level maintained, protected, treated mice against renal inflammation |
| Ibarrola et al., 2019 [ | MCP | In vivo | Male Wistar rats | BNP serum level normalization, lower Gal-3 cardiac expression, reticulocalbin-3 and fumarase in the myocardium, IL-1β and CRP in serum |
| Li et al., 2019 [ | MCP and perindopril | In vivo | New Zealand male rabbits | Gal-3, collagen I, and III downregulation |
| Vergaro et al., 2016 [ | MCP | In vivo | Transgenic mice with aldosterone synthase gene overexpression | Reduced cardiac hypertrophy, fibrosis, Coll-1, and Coll-3 genes expression and also enhanced anti-inflammatory and anti-fibrotic effects when synergistically acting with Canrenoate |
| Ibarrola et al., 2017 [ | MCP | In vivo | Male Wistar rats | Gal-3, mRNA expression normalized, collagen I, fibronectin, α-SMA, TGF-β1, and CTGF mRNA expression reduced compared to pressure overload group, vascular inflammatory markers expression was also controlled |
| Xue et al., 2019 [ | Ginseng pectin fractions | In vitro and In vivo | Jurkat (human leukemia cells) and male IRC mice | MCP inhibited IL-2 expression, and the three pectin fractions utilized reversed cleaved caspase-3 formation alongside lactose. MCP and ginseng pectins inhibited ROS production in vitro. Reduced tumor weight and increased IL-2 secretion in vivo |
| Lau et al., 2021 [ | MCP | Interventional trial | Participants with high Gal-3 levels and hypertension | MCP had no impact regarding attenuating of cardiac-related risk factors |
| Busato et al., 2020 [ | Broccoli stalks pectin | In vitro and in vivo | Female albino swiss mice and peritoneal exsudate cells | Macrophage activation and higher phagocytic activity; IL-10 presence was higher at peritoneal fluid in vivo, but not at in vitro model |
| Liu et al., 2008 [ | MCP | In vitro and in vivo | CT-26 cells and Balb/c female mice | MCP did not alter Gal-3 expression at metastatic liver cells, although it did inhibit tumor growth and metastatic rate |
| Courts, 2013 [ | MCP | In vitro | Caco-2 monolayer | MCP fragments were absorbed through paracellular and to a lower degree by transcellular transports at in vitro culture |
| Huang et al., 2012 [ | Enzyme-treated CP | In vitro and In vivo | HepG2, A549, Colo 205, and HEK293 cells, BALB/c mice | Altered membrane permeability (LDH release) in the cancer cell lines; low weight oligogalacturonide was absorbed by the mice and the tumor cells, enhancing Gal-3 release to the medium |
| Fan et al., 2018 [ | Ginseng RG-I enriched pectins | In vitro | L-929 fibroblast cells | Modulation of cell migration and adhesion, independent of Gal-3 |
| Nishikawa et al., 2018 [ | Modified citrus pectin (MCP) | In vivo | Male C57BL/6 mice | Attenuated blood-brain barrier disruption Gal-3 upregulation, inactivation of ERK 1/2, STAT and MMP |
| Sivaprakasam et al., 2016 [ | 2% inulin, 2% pectin, and 1% cellulose | In vivo | Human colon cancer tissue and Ffar-2−/− C57BL/6J mice | Microbiota modulation, promotion of |
| Kim et al., 2013 [ | SCFAs | In vivo | WT, GPR41−/− and | Activation of intestinal epithelial cells to produce chemokines and cytokines, GPR’s were essential in T effector cell activation and signaling pathways |
| Tian et al., 2016 [ | Sugar beet, soy, low DM, and high DM citrus pectin | In vivo | Male Wistar rats | More stimulation of |
| Tian et al., 2017 [ | Low DM and high DM citrus pectin | In vivo | Piglets | The slower fermentation process, alteration of main fermentation region, and higher Bacteroidetes predominance |
| Ferreira-Lazarte et al., 2019 [ | CP | In vitro | Dynamic gastric simulator with healthy volunteer fecal slurry donated | Growth stimulation of |
| Chen et al., 2013 [ | Apple pectin oligosaccharides | In vitro | Fecal batch culture fermentation | Increased numbers of |
| Onumpai et al., 2011 [ | Potato galactan, methylated citrus pectin, beet arabinan, | In vitro | Fecal batch culture fermentation | Higher |
| Merheb, Abdel-Massih, and Karam, 2019 [ | CP and MCP | In vivo | Female BALB/c mice | Upregulation of IL-17, IFN-γ, and TNF-α through IL-4 cytokine secretion in the spleen |
| Amorim et al., 2016 [ | In vivo | Female albino Swiss mice | Promotion of macrophage differentiation, nitric oxide production, and upregulation of IL-12, TNF-α, and IL-10 secretion | |
| Do Nascimento et al., 2017 [ | Sweet pepper pectin | In vitro | THP-1 human monocytic cell | Modulation of TNF-α, IL-1β, and IL-10 production and secretion |
| Popov et al., 2011 [ | Sweet pepper pectin | In vivo | Male BALB/c mice | Higher IL-10 production with lower TNF-α release |
| Ishisono et al., 2017 [ | CP | In vivo | Male C57BL/6 mice | Suppression of IL-6 secretion from TLR activated macrophages and CD11c+ cells |
| Vogt et al., 2016 [ | Different DM lemon pectin | In vitro | T84 intestinal epithelial cells | NF-kB/AP-1 activation through TLR/MyD88 and protective effects in the intestinal barrier |
| Wang et al., 2018 [ | In vivo | Cyclophosphamide induced immunosuppressive mice | Macrophage activation, MyD88 increased expression and upregulated expression of TLR4 | |
| Park et al., 2013 [ | RG-II from P. ginseng | In vivo and In vitro | C57BL6 WT, TCR KO, TLR KO mice, and BMDC cells | Facilitation of CD8+ T cells, induced production of TNF-α, IL-12, IFN-γ, and IL-1β during dendritic cell maturation |
| Sahasrabudhe et al., 2018 [ | Lemon pectins with different DM | In vitro and In vivo | HEK-Blue WT and mutated cell lines, female C57BL/6 mice | Inhibition of TLR2-1 heterodimer, prevention of ileitis in the mice model |
| Hu et al., 2021 [ | Lemon pectins with different DM | In vivo | Sprague-Dawley male rats and C57BL/6 mice | Reduced peri-capsular fibrosis in vivo and decreased DAMP-induced TLR2 immune activation in vitro |
| Kolatsi-Jannou et al., 2011 [ | MCP | In vivo | Male C57BL/6J mice | Reduced Gal-3 expression, reduced renal cell proliferation, apoptosis, fibrosis, and proinflammatory cytokine expression |
Figure 6Schematic representation of the intestinal environment. Pectin molecules can interact in different ways with epithelial and immune components of intestinal tissues, regulating different responses directly and through fermentation by-products. SCFA—short-chain fatty acid; TLR—toll-like receptor.